Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

Ann Oncol. 2019 Jun 1;30(6):1020. doi: 10.1093/annonc/mdy532.

Authors

J-C Soria, J Cortes, C Massard, J-P Armand, D De Andreis, S Ropert, E Lopez, A Catteau, J James, J-F Marier, M Beliveau, R E Martell, J Baselga

PMID: 30624604
DOI: 10.1093/annonc/mdy532

No abstract available

Publication types

Published Erratum